about
Pazopanib in the management of advanced soft tissue sarcomasRenal Cancer Stem Cells: Characterization and Targeted TherapiesBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaMammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-BromopyruvateA miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling.Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.Linifanib: current status and future potential in cancer therapy.Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.Targeted therapies for renal cell carcinoma.Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics.Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.Maslinic Acid Inhibits Proliferation of Renal Cell Carcinoma Cell Lines and Suppresses Angiogenesis of Endothelial Cells.
P2860
Q26746205-4910C524-FCB2-498B-90D7-03A2AC8A0F9FQ26746970-9F8E9A37-ABCB-4B1B-AEC1-B4398493B705Q26766240-A3F919FC-9C66-431E-84E0-949E069DF26DQ34077263-EF923A4D-0211-4B1A-B6EB-AF60C74D1EF3Q35553882-A2178B4C-6F6C-4CA5-86EF-55F892831355Q36347081-B164DD52-BE95-45D9-8255-196B3B4800DEQ36768803-A0D28B28-67F7-4B71-AF1A-70792B5CA68BQ37416749-1F5E508D-2C2B-4CB4-94BE-34BAFC6CC234Q37437544-E756600E-A535-4E22-B9C9-DA6FC9FE504BQ38455525-53A80127-7942-4C21-8AB0-3A1D49E25EB0Q38817505-0796F2AC-183F-48C9-A3E6-9474028AD94DQ38976447-8C270D0F-6586-4D31-B1B4-D6A44D2EF218Q39044249-509B9C10-9A6F-4B1D-9ABC-96C411EDA289Q39425380-2435FCCA-30A7-4F8D-890B-25B35984F098Q47163897-1C3FBCB0-1A51-403A-A3AA-AEB2D753613DQ52714865-47C5D1F3-D8CB-4DD4-B42B-DF5E5FAF082CQ53743976-853F6E37-6AAE-47D8-ACC2-48094C41761B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting angiogenesis in renal cell carcinoma.
@en
type
label
Targeting angiogenesis in renal cell carcinoma.
@en
prefLabel
Targeting angiogenesis in renal cell carcinoma.
@en
P2093
P2860
P1476
Targeting angiogenesis in renal cell carcinoma.
@en
P2093
Edwin M Posadas
Robert A Figlin
Shaleekha Sharma
Suwicha Limvorasak
P2860
P304
P356
10.1517/14656566.2013.832202
P407
P577
2013-08-28T00:00:00Z